141 related articles for article (PubMed ID: 35478274)
1. Controversy of tissue-agnostic approvals in immunotherapy and targeted therapy.
Bose CK
Med Oncol; 2022 Apr; 39(5):67. PubMed ID: 35478274
[TBL] [Abstract][Full Text] [Related]
2. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach.
Luchini C; Bibeau F; Ligtenberg MJL; Singh N; Nottegar A; Bosse T; Miller R; Riaz N; Douillard JY; Andre F; Scarpa A
Ann Oncol; 2019 Aug; 30(8):1232-1243. PubMed ID: 31056702
[TBL] [Abstract][Full Text] [Related]
3. Identification and Utilization of Biomarkers to Predict Response to Immune Checkpoint Inhibitors.
Gjoerup O; Brown CA; Ross JS; Huang RSP; Schrock A; Creeden J; Fabrizio D; Tolba K
AAPS J; 2020 Oct; 22(6):132. PubMed ID: 33057937
[TBL] [Abstract][Full Text] [Related]
4. Use of pembrolizumab among older adults with cancer in the United States, before and after FDA approval of its tumor-agnostic indication.
Hong YD; Enewold L; Halpern MT; Zeruto C; Mariotto AB
Pharmacoepidemiol Drug Saf; 2024 Jan; 33(1):e5745. PubMed ID: 38156547
[TBL] [Abstract][Full Text] [Related]
5. A scoping review and meta-analysis on the prevalence of pan-tumour biomarkers (dMMR, MSI, high TMB) in different solid tumours.
Kang YJ; O'Haire S; Franchini F; IJzerman M; Zalcberg J; Macrae F; Canfell K; Steinberg J
Sci Rep; 2022 Nov; 12(1):20495. PubMed ID: 36443366
[TBL] [Abstract][Full Text] [Related]
6. [Current Status and Challenges in Tumor Agnostic Treatment].
Komine K
Gan To Kagaku Ryoho; 2023 Jun; 50(6):657-661. PubMed ID: 37317595
[TBL] [Abstract][Full Text] [Related]
7. Impact of tissue-agnostic approvals for patients with sarcoma.
Pestana RC; Beal JR; Parkes A; Hamerschlak N; Subbiah V
Trends Cancer; 2022 Feb; 8(2):135-144. PubMed ID: 34887213
[TBL] [Abstract][Full Text] [Related]
8. Precision medicine becomes reality-tumor type-agnostic therapy.
Yan L; Zhang W
Cancer Commun (Lond); 2018 Mar; 38(1):6. PubMed ID: 29764494
[TBL] [Abstract][Full Text] [Related]
9. JSCO-ESMO-ASCO-JSMO-TOS: international expert consensus recommendations for tumour-agnostic treatments in patients with solid tumours with microsatellite instability or NTRK fusions.
Yoshino T; Pentheroudakis G; Mishima S; Overman MJ; Yeh KH; Baba E; Naito Y; Calvo F; Saxena A; Chen LT; Takeda M; Cervantes A; Taniguchi H; Yoshida K; Kodera Y; Kitagawa Y; Tabernero J; Burris H; Douillard JY
Ann Oncol; 2020 Jul; 31(7):861-872. PubMed ID: 32272210
[TBL] [Abstract][Full Text] [Related]
10. Tumor Mutational Burden and Mismatch Repair Deficiency Discordance as a Mechanism of Immunotherapy Resistance.
Bielska AA; Chatila WK; Walch H; Schultz N; Stadler ZK; Shia J; Reidy-Lagunes D; Yaeger R
J Natl Compr Canc Netw; 2021 Feb; 19(2):130-133. PubMed ID: 33545685
[TBL] [Abstract][Full Text] [Related]
11. Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D; Corsini LR; Scalia R; Brando C; Cucinella A; Madonia G; Dimino A; Filorizzo C; Barraco N; Bono M; Fiorino A; Magrin L; Sciacchitano R; Perez A; Russo TDB; Pantuso G; Russo A; Bazan V
Crit Rev Oncol Hematol; 2022 Feb; 170():103597. PubMed ID: 35033663
[TBL] [Abstract][Full Text] [Related]
12. Immune checkpoint inhibition in advanced colorectal cancer with inherited and acquired microsatellite instability: Current state and future directions.
Dasanu CA; Alani M; Habibi S; Codreanu I
J Oncol Pharm Pract; 2023 May; ():10781552231178293. PubMed ID: 37246506
[TBL] [Abstract][Full Text] [Related]
13. The Role of Histology-Agnostic Drugs in the Treatment of Metastatic Castration-Resistant Prostate Cancer.
Iannantuono GM; Torino F; Rosenfeld R; Guerriero S; Carlucci M; Sganga S; Capotondi B; Riondino S; Roselli M
Int J Mol Sci; 2022 Aug; 23(15):. PubMed ID: 35955671
[TBL] [Abstract][Full Text] [Related]
14. Biomarkers for Predicting Response to Immunotherapy with Immune Checkpoint Inhibitors in Cancer Patients.
Duffy MJ; Crown J
Clin Chem; 2019 Oct; 65(10):1228-1238. PubMed ID: 31315901
[TBL] [Abstract][Full Text] [Related]
15. Evaluating mismatch repair deficiency for solid tumor immunotherapy eligibility: immunohistochemistry versus microsatellite molecular testing.
Saeed OAM; Mann SA; Luchini C; Huang K; Zhang S; Sen JD; Piredda ML; Wang M; Baldrige LA; Sperling RM; Curless KL; Cheng L
Hum Pathol; 2021 Sep; 115():10-18. PubMed ID: 34052294
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Blockade Therapy in Patients With Colorectal Cancer Harboring Microsatellite Instability/Mismatch Repair Deficiency in 2022.
André T; Cohen R; Salem ME
Am Soc Clin Oncol Educ Book; 2022 Apr; 42():1-9. PubMed ID: 35471834
[TBL] [Abstract][Full Text] [Related]
17. Tumor mutational burden as a predictive biomarker for checkpoint inhibitor immunotherapy.
Lee M; Samstein RM; Valero C; Chan TA; Morris LGT
Hum Vaccin Immunother; 2020; 16(1):112-115. PubMed ID: 31361563
[TBL] [Abstract][Full Text] [Related]
18. Tumor Mutational Burden Predicting the Efficacy of Immune Checkpoint Inhibitors in Colorectal Cancer: A Systematic Review and Meta-Analysis.
Li Y; Ma Y; Wu Z; Zeng F; Song B; Zhang Y; Li J; Lui S; Wu M
Front Immunol; 2021; 12():751407. PubMed ID: 34659255
[TBL] [Abstract][Full Text] [Related]
19. Tumor-Agnostic Precision Medicine from the AACR GENIE Database: Clinical Implications.
Gouda MA; Nelson BE; Buschhorn L; Wahida A; Subbiah V
Clin Cancer Res; 2023 Aug; 29(15):2753-2760. PubMed ID: 37061987
[TBL] [Abstract][Full Text] [Related]
20. DNA mismatch repair in cancer.
Baretti M; Le DT
Pharmacol Ther; 2018 Sep; 189():45-62. PubMed ID: 29669262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
